BOCA RATON, Fla., July 21, 2016 /PRNewswire/ -- Sensus
Healthcare, Inc. (NASDAQ: SRTSU), a medical device company
specializing in the treatment of non-melanoma skin cancers and
other skin conditions, such as keloids, with superficial radiation
therapy, today announced that the 2,300,000 units issued in its
underwritten initial public offering will separate in accordance
with their terms on July 25, 2016.
Each unit consists of one share of common stock, $0.01 par value per share, and a three-year
warrant to purchase one share of common stock at an initial
exercise price of $6.75 per
share.
At the commencement of trading on July
25, 2016, the common stock and warrants will trade
separately on The NASDAQ Capital Market under the symbols "SRTS"
and "SRTSW," respectively. The units, which are currently trading
under the symbol "SRTSU," will no longer be listed on The NASDAQ
Capital Market following the separation.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Sensus
Sensus Healthcare, Inc. is a medical
device company that is committed to enabling non-invasive and
cost-effective treatment of non-melanoma skin cancers and keloids.
Sensus uses a proprietary low energy x-ray radiation technology
known as superficial radiation therapy (SRT), which is a result of
over a decade of dedicated research and development activities.
Sensus has successfully incorporated the SRT therapy into its
portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™.
To date, the SRT technology has been used to effectively and safely
treat oncological and non-oncological skin conditions in thousands
of patients. For more information, visit
http://www.sensushealthcare.com.
Investor Relations:
Jeffrey
Goldberger / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1267
Email: jgoldberger@kcsa.com / asoss@kcsa.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sensus-healthcare-inc-announces-separation-of-units-sold-in-ipo-300301824.html
SOURCE Sensus Healthcare, Inc.